Summary: Zevra Therapeutics announced that Rene Braeckman, PhD, the company’s senior vice president of clinical development, will present top-line data from the phase 2 clinical trial of KP1077 (serdexmethylphenidate) in patients with idiopathic hypersomnia (IH) at Sleep Europe … [Read more...]
Apnimed Completes Enrollment Early in Phase 3 Study for Oral OSA Treatment
Summary: Apnimed has completed enrollment for its phase 3 SynAIRgy study, which will evaluate the efficacy and safety of its lead candidate AD109, a potential first oral therapy for obstructive sleep apnea (OSA). The trial will focus on adults with mild, moderate, and severe OSA. … [Read more...]
Phase 2 Study of ALKS 2680 Begins for Narcolepsy Type 2
Summary: Alkermes plc has initiated the Vibrance-2 study, a phase 2 clinical trial designed to evaluate the safety and efficacy of ALKS 2680, a novel oral orexin 2 receptor agonist, in treating narcolepsy type 2. The study will involve approximately 80 adults with narcolepsy type … [Read more...]
First Patient Dosed in Phase 3 Study of Lumryz for IH
Summary: Avadel Pharmaceuticals has commenced dosing in the REVITALYZ phase 3 study to evaluate the efficacy and safety of Lumryz, an extended-release sodium oxybate, as a treatment for idiopathic hypersomnia (IH). The study, involving approximately 150 adults, aims to assess the … [Read more...]
Sleep Monitoring Integrated into Phase 2 Obesity Drug Trial
Summary: Beacon Biosignals and Skye Bioscience are partnering to integrate sleep quality and sleep apnea endpoints in a phase 2 trial of obesity drug candidate Nimacimab. The trial will utilize sleep monitoring technology to provide an assessment of the drug’s impact on … [Read more...]
Apnimed Completes Enrollment for Phase 3 Sleep Apnea Drug Trial
Summary: Apnimed, a medical-stage pharmaceutical enterprise, has done early enrollment for its LunAIRo stage 3 research, assessing the efficacy and safety of its direct candidate Advert109 for managing obstructive sleep apnea (OSA). Advertisement109, a probable very first oral … [Read more...]
Zevra’s KP1077 Progresses With Positive Phase 2 Data in IH
Summary: In Q1 2024, Zevra Therapeutics claimed constructive topline info from its section 2 research of KP1077 in idiopathic hypersomnia, demonstrating promising tolerance and early indicators of significant advantages. The complete results will be offered at Snooze 2024, and an … [Read more...]
Zevra to Present Data from KP1077 Phase 2 Trial in IH at SLEEP
Summary: At Slumber 2024, Zevra Therapeutics will existing the whole information from the KP1077 section 2 trial for idiopathic hypersomnia, signaling potential progress into stage 3 trials. A shareholder letter from CEO Neil McFarlane underscores this milestone, alongside … [Read more...]
Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
Summary: Alkermes plc has launched the Vibrance-1 examine, a stage 2 medical trial to evaluate the basic safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in treating narcolepsy type 1. This oral treatment method aims to boost wakefulness by focusing on the … [Read more...]
FDA OKs Phase 1 Trial of Narcolepsy Drug Candidate ORX750
Summary: Centessa Prescription drugs has received Food and drug administration authorization to commence a section 1 demo of ORX750, an investigational oral therapy aimed at narcolepsy and other slumber-wake conditions. ORX750, a selective orexin receptor 2 agonist, addresses the … [Read more...]